

GLAXOSMITHKLINE PLC  
Form 6-K  
April 01, 2010

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending April 2010

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.

On 31 March 2010, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £12.67 per Ordinary share and \$38.29 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2010 to 31 March 2010:

| <b>Non Executive Director</b> | <b>Ordinary Shares</b> | <b>American Depository Shares (ADSs)</b> |
|-------------------------------|------------------------|--|
| Sir Christopher Gent          | 2,663.77               |  |
| Prof. Sir Roy Anderson        | 813.93                 |  |
| Dr Stephanie Burns            |                        | 399.73                                   |
| Mr Lawrence Culp              |                        | 799.46                                   |
| Sir Crispin Davis             | 3,058.41               |  |
| Sir Deryck Maughan            |                        | 799.46                                   |
| Mr James Murdoch              | 2,663.77               |  |
| Dr Daniel Podolsky            |                        | 839.43                                   |
| Mr Tom de Swaan               | 1,060.58               |  |
| Sir Robert Wilson             | 813.93                 |  |

The Company and the Non-Executive Directors were informed of these allocations on 1 April 2010.

This notification relates to transactions notified in accordance with

Disclosure and Transparency Rule 3.1.4R(1)(a).

S M Bicknell  
Company Secretary  
1 April 2010

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: April 01, 2010

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc